Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

1.910 -0.090 (-4.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CERo Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Top movers in Thursday's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish
The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025. 
Via Stocktwits
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Highlights Progress
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Friday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Nasdaq Tumbles Over 200 Points; Alibaba Posts Upbeat Sales
 
Via Benzinga
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Why Domino's Pizza Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
 
Via Benzinga
CERo Therapeutics Stock Is Soaring Monday: What's Going On?
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares are moving higher Monday after the company presented preclinical data for its lead compound. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.